Soleno Therapeutics (SLNO) Receivables (2013 - 2026)
Soleno Therapeutics (SLNO) reported Receivables of $47.1 million for Q1 2026, up 67.11% on a QoQ basis from $28.2 million in Q4 2025.
Soleno Therapeutics (SLNO) has 8 years of Receivables data on file, last reported at $47.1 million in Q1 2026.
- Quarterly Receivables changed N/A year-over-year to $47.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.1 million (changed N/A YoY) and the FY2025 annual result came in at $28.2 million, changed N/A from the prior year.
- Receivables climbed to $47.1 million in Q1 2026 per SLNO's latest filing, from $28.2 million in the prior quarter.
- Across five years, Receivables topped out at $47.1 million in Q1 2026 and bottomed at $24.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 47.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.14 Mn |
| Dec 31, 2025 | 28.21 Mn |
| Sep 30, 2025 | 25.51 Mn |
| Jun 30, 2025 | 24.62 Mn |
| Dec 31, 2018 | 64,000.00 |
| Jun 30, 2017 | 3,000.00 |
| Mar 31, 2017 | 110,000.00 |
| Dec 31, 2016 | 3,000.00 |
| Sep 30, 2016 | 137,000.00 |
| Jun 30, 2016 | 288,000.00 |
| Mar 31, 2016 | 187,000.00 |
| Dec 31, 2015 | 156,127.00 |
| Sep 30, 2015 | 94,000.00 |
| Jun 30, 2015 | 12,000.00 |
| Mar 31, 2015 | 8,000.00 |
| Sep 30, 2014 | 37,000.00 |
| Dec 31, 2013 | 149,605.00 |